


therapeutics for the prevention and/or treatment of diseases associated with the overexpression and/or aberrant (e.g., increased or unwanted) activity of a kinase (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). The compounds described herein may be useful in treating and/or preventing a disease or condition, e.g., in treating and/or preventing a disease (e.g., proliferative disease (e.g., cancers), metabolic disorder (e.g., diabetes), autoimmune disease, or neurological disease (e.g., Alzheimer's disease, gliosis, spinal cord injury)), in a subject in need thereof. The compounds described herein may be useful in male contraception (e.g., reducing or inhibiting spermatogenesis, or reducing the rate of male fertility) in a healthy fertile male subject. Also provided are uses, pharmaceutical compositions and kits including a compound described herein.


[0005] In one aspect, the present disclosure provides compounds of Formula (I'):



and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, wherein R^1 , R^2 , R^3 , R , n , L , X , and $Y1$ are as defined herein. R^3 is a

warhead which covalently or non-covalently binds a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). In certain embodiments, the warhead non-covalently binds to a CDK, e.g., CDK15, CDK16, CDK17, CDK18. In certain embodiments, the warhead covalently binds to a CDK, e.g., CDK14. In certain embodiments, $R^{3'}$ is R^3 . In certain embodiments, a compound of Formula (I') is of Formula (I).

[0006] In one aspect, the present disclosure provides compounds of Formula (I):



and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, wherein R^1 , R^2 , R^3 , R , n , L , X , and $Y1$ are as defined herein. R^3 is a warhead which covalently or non-covalently binds a CDK (e.g., CDK14, CDK15, CDK16, CDK17, CDK18). In certain embodiments, the warhead non-covalently binds to a CDK, e.g., CDK15, CDK16, CDK17, CDK18. In certain embodiments, the warhead covalently binds to a CDK, e.g., CDK14.

[0007] Exemplary compounds of Formulae (I) and (I') include, but are not limited to:

